Photo of James D. Iglehart,  MD

James D. Iglehart, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-5178
Fax: (617) 632-3709


jiglehart@partners.org

James D. Iglehart, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Anne E. Dyson Professor in Women's Cancers, Surgery, Harvard Medical School
  • Charles Dana Investigator in Cancer Genetics, Cancer Biology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am the Principal Investigator for the Dana-Farber/Harvard SPORE in Breast Cancer. I led the Women's Cancers Program at Dana-Farber and Co-lead the Breast Cancer Program in the Cancer Center. My own research focuses on breast cancer genetics and genomics, and on translational cancer research in general. Current projects include the role of NF-kB signaling in breast cancer, the role of DNA damage pathways in certain breast and ovarian cancers, BRCA1 and BRCA2 susceptibility genes, and copy number alterations in breast and ovarian cancer. This work is carried out by several investigators in the Women's Cancers Program at Dana-Farber.

Publications

Powered by Harvard Catalyst
  • Bailey ST, Miron PL, Choi YJ, Kochupurakkal B, Maulik G, Rodig SJ, Tian R, Foley KM, Bowman T, Miron A, Brown M, Iglehart JD, Biswas DK. NF-虜B activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth. Mol Cancer Res 2014; 12:408-20. PubMed
  • Dreze M, Calkins AS, Gálicza J, Echelman DJ, Schnorenberg MR, Fell GL, Iwai S, Fisher DE, Szüts D, Iglehart JD, Lazaro JB. Monitoring repair of UV-induced 6-4-photoproducts with a purified DDB2 protein complex. PLoS ONE 2014; 9:e85896. PubMed
  • Calkins AS, Iglehart JD, Lazaro JB. DNA damage-induced inhibition of rRNA synthesis by DNA-PK and PARP-1. Nucleic Acids Res 2013; 41:7378-86. PubMed
  • Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLoS ONE 2013; 8:e80023. PubMed
  • Jeselsohn RM, Werner L, Regan MM, Fatima A, Gilmore L, Collins LC, Beck AH, Bailey ST, He HH, Buchwalter G, Brown M, Iglehart JD, Richardson A, Come SE. Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response. PLoS ONE 2013; 8:e64225. PubMed
  • Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, Defazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD, , Matulonis UA. Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome. Clin Cancer Res 2012; 18:5806-5815. PubMed
  • Dominici L, Liao GS, Brock J, Iglehart JD, Lotfi P, Meyer J, Pandalai P, Golshan M. Large Needle Core Biopsy of Atypical Ductal Hyperplasia: Results of Surgical Excision. Breast J 2012. PubMed
  • Adelmant G, Calkins AS, Garg BK, Card JD, Askenazi M, Miron A, Sobhian B, Zhang Y, Nakatani Y, Silver PA, Iglehart JD, Marto JA, Lazaro JB. DNA ends alter the molecular composition and localization of Ku multicomponent complexes. Mol Cell Proteomics 2012; 11:411-21. PubMed
  • Utermark T, Rao T, Cheng H, Wang Q, Lee SH, Wang ZC, Iglehart JD, Roberts TM, Muller WJ, Zhao JJ. The p110留 and p110硫 isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev 2012; 26:1573-86. PubMed
  • Richardson AL, Iglehart JD. BEAMing up personalized medicine: mutation detection in blood. Clin Cancer Res 2012; 18:3209-11. PubMed
  • Birdwell RL, Mountford CE, Iglehart JD. Molecular imaging of the breast. Radiol Clin North Am 2010; 48:1075-88. PubMed
  • Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ, Park SY, Cho EY, Lewis G, Kehoe S, Iglehart JD, Dillon D, Allred DC, Macconaill L, Gelman R, Polyak K. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res 2010; 70:5674-8. PubMed
  • Qiao M, Wang Y, Xu X, Lu J, Dong Y, Tao W, Stein J, Stein GS, Iglehart JD, Shi Q, Pardee AB. Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol Cell 2010; 38:512-23. PubMed
  • Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, Richardson AL, Wang ZC. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 2010; 16:214-8. PubMed
  • Chittenden TW, Pak J, Rubio R, Cheng H, Holton K, Prendergast N, Glinskii V, Cai Y, Culhane A, Bentink S, Schwede M, Mar JC, Howe EA, Aryee M, Sultana R, Lanahan AA, Taylor JM, Holmes C, Hahn WC, Zhao JJ, Iglehart JD, Quackenbush J. Therapeutic implications of GIPC1 silencing in cancer. PLoS ONE 2011; 5:e15581. PubMed
  • Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, Gown A, Hammond ME, Iglehart JD, Moench S, Pierce LJ, Ravdin P, Schnitt SJ, Wolff AC. NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw 2009; 7 Suppl 6:S1-S21; quiz S22-3. PubMed
  • Birdwell RL, Mountford CE, Iglehart JD. Molecular imaging of the breast. AJR Am J Roentgenol 2009; 193:367-76. PubMed
  • Iglehart JD, Silver DP. Synthetic lethality--a new direction in cancer-drug development. N Engl J Med 2009; 361:189-91. PubMed
  • Bafford AC,Burstein HJ,Barkley CR,Smith BL,Lipsitz S,Iglehart JD,Winer EP,Golshan M. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat 2008; 115:7-12. PubMed
  • Dejmek J, Iglehart JD, Lazaro JB. DNA-dependent protein kinase (DNA-PK)-dependent cisplatin-induced loss of nucleolar facilitator of chromatin transcription (FACT) and regulation of cisplatin sensitivity by DNA-PK and FACT. Mol Cancer Res 2009; 7:581-91. PubMed
  • Nunes RA,Li X,Kang SP,Burstein H,Roberts L,Carney W,Blackwell K,Ryan P,Borges V,Iglehart JD,Friedman P,Harris LN. Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. Int J Biol Markers 2009; 24:1-10. PubMed
  • Cheng H, Liu P, Wang ZC, Zou L, Santiago S, Garbitt V, Gjoerup OV, Iglehart JD, Miron A, Richardson AL, Hahn WC, Zhao JJ. SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal 2009; 2:ra35. PubMed
  • Lu X, Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat 2008; 108:191-201. PubMed
  • Rosner B,Colditz GA,Iglehart JD,Hankinson SE. Risk prediction models with incomplete data with application to prediction of estrogen receptor-positive breast cancer: prospective data from the Nurses' Health Study. Breast Cancer Res 2008; 10:R55. PubMed
  • Tamimi RM, Brugge JS, Freedman ML, Miron A, Iglehart JD, Colditz GA, Hankinson SE. Circulating colony stimulating factor-1 and breast cancer risk. Cancer Res 2008; 68:18-21. PubMed
  • Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, Birdwell R, Lester S, Lipsitz S, Iglehart JD, Golshan M. Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol 2007; 96:474-80. PubMed
  • Chan MM, Lu X, Merchant FM, Iglehart JD, Miron PL. Serial transplantation of NMU-induced rat mammary tumors: a model of human breast cancer progression. Int J Cancer 2007; 121:474-85. PubMed
  • Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, Iglehart JD, Weinberg RA. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 2007; 12:160-70. PubMed
  • Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD, Biswas DK. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol Cancer Ther 2007; 6:1973-82. PubMed
  • Qiao M, Iglehart JD, Pardee AB. Metastatic potential of 21T human breast cancer cells depends on Akt/protein kinase B activation. Cancer Res 2007; 67:5293-9. PubMed
  • Chang SB, Miron P, Miron A, Iglehart JD. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. J Surg Res 2006; 138:37-44. PubMed
  • Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007; 13:1198-207. PubMed
  • Biswas DK, Iglehart JD. Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. J Cell Physiol 2006; 209:645-52. PubMed
  • Shi Q, Harris LN, Lu X, Li X, Hwang J, Gentleman R, Iglehart JD, Miron A. Declining plasma fibrinogen alpha fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery. J Proteome Res 2006; 5:2947-55. PubMed
  • Golshan M, Miron A, Nixon AJ, Garber JE, Cash EP, Iglehart JD, Harris JR, Wong JS. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. Am J Surg 2006; 192:58-62. PubMed
  • Wang ZC, Buraimoh A, Iglehart JD, Richardson AL. Genome-Wide Analysis for Loss of Heterozygosity in Primary and Recurrent Phyllodes Tumor and Fibroadenoma of Breast using Single Nucleotide Polymorphism Arrays. Breast Cancer Res Treat 2006; 97:301-9. PubMed
  • Wang ZC, Buraimoh A, Iglehart JD, Richardson AL. Genome-Wide Analysis for Loss of Heterozygosity in Primary and Recurrent Phyllodes Tumor and Fibroadenoma of Breast using Single Nucleotide Polymorphism Arrays. Breast Cancer Res Treat 2006. PubMed
  • Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006; 9:121-32. PubMed
  • Zhang X, Lu X, Shi Q, Xu XQ, Leung HC, Harris LN, Iglehart JD, Miron A, Liu JS, Wong WH. Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics 2006; 7:197. PubMed
  • Vansonnenberg E, Shankar S, Parker L, Cheung L, Morrison PR, Silverman SG, Igelhart D. Palliative radiofrequency ablation of a fungating, symptomatic breast lesion. AJR Am J Roentgenol 2005; 184:S126-8. PubMed
  • Chan MM, Iglehart JD. Viral oncolysis: tumor-tailored therapy. Curr Surg 2005; 62:25-30. PubMed
  • Ganesan S, Richardson AL, Wang ZC, Iglehart JD, Miron A, Feunteun J, Silver D, Livingston DM. Abnormalities of the Inactive X Chromosome Are a Common Feature of BRCA1 Mutant and Sporadic Basal-like Breast Cancer. Cold Spring Harb Symp Quant Biol 2006; 70:93-7. PubMed
  • Wang ZC, Lin M, Wei LJ, Li C, Miron A, Lodeiro G, Harris L, Ramaswamy S, Tanenbaum DM, Meyerson M, Iglehart JD, Richardson A. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 2004; 64:64-71. PubMed
  • Nahta R, Iglehart JD, Kempkes B, Schmidt EV. Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. Cancer Res 2002; 62:2267-71. PubMed
  • Bluman LG, Borstelmann NA, Rimer BK, Iglehart JD, Winer EP. Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ. J Womens Health Gend Based Med 2001; 10:589-98. PubMed
  • Harris LN, Yang L, Liotcheva V, Pauli S, Iglehart JD, Colvin OM, Hsieh TS. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res 2001; 7:1497-504. PubMed
  • Seth P, Lunetta KL, Bell DW, Gray H, Nasser SM, Rhei E, Kaelin CM, Iglehart DJ, Marks JR, Garber JE, Haber DA, Polyak K. Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. Cancer Res 2001; 60:6859-63. PubMed
  • Davis PL, Miron A, Andersen LM, Iglehart JD, Marks JR. Isolation and initial characterization of the BRCA2 promoter. Oncogene 1999; 18:6000-12. PubMed
  • Parmigiani G, Berry DA, Winer EP, Tebaldi C, Iglehart JD, Prosnitz LR. Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. J Clin Oncol 1999; 17:1465-73. PubMed
  • Bluman LG, Rimer BK, Berry DA, Borstelmann N, Iglehart JD, Regan K, Schildkraut J, Winer EP. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol 1999; 17:1040-6. PubMed
  • Iglehart JD, Miron A, Rimer BK, Winer EP, Berry D, Shildkraut MJ. Overestimation of hereditary breast cancer risk. Ann Surg 1998; 228:375-84. PubMed
  • Davis PL, Shaiu WL, Scott GL, Iglehart JD, Hsieh TS, Marks JR. Complex response of breast epithelial cell lines to topoisomerase inhibitors. Anticancer Res 1998; 18:2919-32. PubMed
  • Burke HB, Hoang A, Iglehart JD, Marks JR. Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. Cancer 1998; 82:874-7. PubMed
  • Peters KG, Coogan A, Berry D, Marks J, Iglehart JD, Kontos CD, Rao P, Sankar S, Trogan E. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer 1998; 77:51-6. PubMed
  • Lo JY, Baker JA, Kornguth PJ, Iglehart JD, Floyd CE. Predicting breast cancer invasion with artificial neural networks on the basis of mammographic features. Radiology 1997; 203:159-63. PubMed
  • Marks JR, Huper G, Vaughn JP, Davis PL, Norris J, McDonnell DP, Wiseman RW, Futreal PA, Iglehart JD. BRCA1 expression is not directly responsive to estrogen. Oncogene 1997; 14:115-21. PubMed
  • Vaughn JP, Stekler J, Demirdji S, Mills JK, Caruthers MH, Iglehart JD, Marks JR. Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides. Nucleic Acids Res 1996; 24:4558-64. PubMed
  • Davis P, Bazar K, Huper G, Lozano G, Marks J, Iglehart JD. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells. Oncogene 1996; 13:1315-22. PubMed
  • Elbendary AA, Cirisano FD, Evans AC, Davis PL, Iglehart JD, Marks JR, Berchuck A. Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin Cancer Res 1998; 2:1571-5. PubMed
  • Vaughn JP, Davis PL, Jarboe MD, Huper G, Evans AC, Wiseman RW, Berchuck A, Iglehart JD, Futreal PA, Marks JR. BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. Cell Growth Differ 1996; 7:711-5. PubMed
  • Vaughn JP, Iglehart JD, Demirdji S, Davis P, Babiss LE, Caruthers MH, Marks JR. Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay. Proc Natl Acad Sci U S A 1995; 92:8338-42. PubMed
  • Iglehart JD, Kerns BJ, Huper G, Marks JR. Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer. Breast Cancer Res Treat 1995; 34:253-63. PubMed
  • Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns BJ, Iglehart JD. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 1994; 219:332-41. PubMed
  • Futreal PA, Cochran C, Marks JR, Iglehart JD, Zimmerman W, Barrett JC, Wiseman RW. Mutation analysis of the THRA1 gene in breast cancer: deletion/fusion of the gene to a novel sequence on 17q in the BT474 cell line. Cancer Res 1994; 54:1791-4. PubMed
  • Kerns BJ, Jordan PA, Huper G, Marks JR, Iglehart JD, Layfied LJ. Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer. Mod Pathol 1993; 6:673-8. PubMed
  • Kerns BJ, Jordan PA, Moore MB, Humphrey PA, Berchuck A, Kohler MF, Bast RC, Iglehart JD, Marks JR. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem 1992; 40:1047-51. PubMed
Hide